GSK's Asthma Drug Shows Promise in Reducing Severe Attacks, Eyes £3 Billion in Sales

May 21, 2024, 07:31 AM

GSK's experimental asthma drug has shown promising results in late-stage clinical trials, meeting its primary goal of reducing severe asthma attacks over a 52-week period. The British pharmaceutical company expects the drug to become a blockbuster product, potentially generating peak annual sales of £3 billion ($3.81 billion). The successful trials, named SWIFT-1 and SWIFT-2, met key objectives and mark a significant milestone for GSK's long-acting asthma treatment.